Mechanism of Action
Membrane Disruption and LPS Neutralization
Tachyplesin I binds LPS through its cationic residues, neutralizing endotoxin activity. The beta-hairpin structure inserts into bacterial membranes forming pores, with the two disulfide bonds maintaining structural rigidity essential for potency. This dual LPS-binding and membrane-disrupting activity contributes to its broad-spectrum efficacy.
CXCR4 Antagonism (T22 Lineage)
The tachyplesin scaffold inspired the development of T22 and its analogs (T140, TN14003, AMD3100 precursors) as CXCR4 antagonists. CXCR4 mediates HIV entry and cancer cell metastasis. Tachyplesin-derived peptides block HIV gp120 binding to CXCR4, preventing T-cell infection. Modified analogs show sub-nanomolar CXCR4 binding affinity and are in various stages of drug development.
Research Summary
Antiviral Activity
PreclinicalTachyplesin demonstrates activity against HIV, HSV-1, HSV-2, and influenza viruses. The CXCR4-blocking activity of tachyplesin analogs prevents HIV entry with IC50 values in the nanomolar range. This lineage led to the clinical development of AMD3100 (plerixafor/Mozobil), an FDA-approved CXCR4 antagonist for stem cell mobilization.
Antitumor Properties
PreclinicalDirect antitumor activity through membrane disruption of cancer cells and indirect effects via CXCR4 blockade have been demonstrated for various tumor models. Hepatocellular carcinoma, lung cancer, and gastric cancer cell lines show sensitivity in vitro. The clinical significance of these findings remains to be established in vivo.
Calculate your Tachyplesin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial (in vitro) | 1-5 ug/mL MIC | Single exposure | Direct application |
| CXCR4 antagonism | 10-100 nM (in vitro) | Continuous exposure | Research only |
No human research protocols. AMD3100 (plerixafor) is the approved drug in this lineage, not tachyplesin itself.
Interactions
Safety Profile
Hemolytic activity and cytotoxicity to mammalian cells at higher concentrations limit systemic use of unmodified tachyplesin. The T22 and subsequent analogs with reduced membrane toxicity were designed specifically to overcome this limitation. No human clinical data for tachyplesin itself.
References
- [1]Nakamura T, et al. (1988). Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab. J Biol Chem, 263(32), 16709-16713.
- [2]Tamamura H, et al. (1998). A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun, 253(3), 877-882.